Wave Life Sciences price target cut to $17 from $27 at Truist Securities, stock rated buy

Wave Life Sciences Ltd. is a biotechnology company, which engages in the development of proprietary synthetic chemistry drug. It focuses on the design, development, and commercialization of nucleic acid-based therapeutics. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Singapore.

This is not a CAPTIS article. Originally, it was published here.